<DOC>
	<DOCNO>NCT01660607</DOCNO>
	<brief_summary>For patient hematologic malignancy undergo allogeneic myeloablative ( MA ) HCT T cell deplete graft , infusion naturally occur regulatory T cell conventional T cell ( T cell addback ) pre-defined dos ratio reduce incidence acute graft v host disease augment graft v leukemia effect improve immune reconstitution .</brief_summary>
	<brief_title>Phase I/II MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional Regulatory T Cell</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<criteria>Recipient Inclusion Criteria 1 . Patients follow disease histopathologically confirm eligible Acute leukemia , primary refractory beyond CR1 High risk acute myeloid leukemia CR1 follow feature : Complex karyotype ( â‰¥3 clonal chromosomal abnormality ) Any follow high risk chromosomal abnormality : Monosomal karyotype ( 5 , 5q , 7 , 7q ) ( 11q23 ) , ( 9 ; 11 ) , inv ( 3 ) , ( 3 ; 3 ) ( 6 ; 9 ) ( 9 ; 22 ) Normal karyotype FLT3ITD mutation Chronic myelogenous leukemia ( accelerate , blast second chronic phase ) Myelodysplastic syndrome Myeloproliferative syndrome NonHodgkin lymphoma poor risk feature suitable autologous HCT 2 . Age &gt; 18 yo &lt; 60 yo patient Cohort 1 . At start Cohort 2A beyond , eligibility expand allow pediatric patient age &gt; 13 yo . 3 . Cardiac ejection fraction &gt; 45 % 4 . Lung diffusion capacity &gt; 50 % 5 . Calculated creatinine clearance &gt; 50 cc/min 6 . SGPT SGOT &lt; 2.5 x ULN , unless elevate secondary disease . Total bilirubin &lt; 2 x ULN ( patient Gilbert 's syndrome may include discretion PI hemolysis exclude 7 . Availability 6/6 HLA match sibling defined Class I ( HLA A B ) serologic type ( high resolution ) Class II ( HLADRB1 ) molecular typing . 8 . Karnofsky performance status &gt; 70 % 9 . No prior myeloablative therapy hematopoietic cell transplantation Recipient Exclusion Criteria 1 . Seropositive following : HIV ab , hepatitis B sAg , hep C ab 2 . Uncontrolled bacterial , viral fungal infection define currently take antimicrobial therapy progression clinical symptom . 3 . Uncontrolled CNS disease involvement 4 . The recipient pregnant lactate female . 5 . Psychosocial circumstance preclude patient able go transplant participate responsibly follow care Donor Inclusion Criteria 1 . Age &gt; 13 yo &lt; 75 year 2 . Karnofsky performance status &gt; 70 % define institutional standard 3 . Seronegative HIV Ag , HIV 1 HIV 2 ab , HTLV 1 HTLV 2 ab hepatitis B sAg PCR+ hepatitis C ab PCR+ , negative Syphillis treponemal screen negative HIV 1 hepatitis C NAT ( nucleic acid test ) within 30 day apheresis collection 4 . Must 6/6 match sibling donor determine HLA type 5 . Female donor childbearing potential must negative serum urine betaHCG test within three week mobilization 6 . Capable undergoing leukapheresis , adequate venous access , willing undergo insertion central catheter leukapheresis via peripheral vein inadequate 7 . The donor legal guardian great 18 year age , capable signing IRBapproved consent form . 8 . Donor selection compliance 21 CFR 1271 . Donor Exclusion Criteria 1 . Evidence active infection viral hepatitis 2 . HIV positive 3 . Lactating female</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>